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Background and aims: Inflammation may influence the cardio-metabolic profile 75 
which relates with the risk of chronic diseases. To assess the inflammatory status by 76 
metabolic health/body mass index (BMI) category and to assess how inflammation can 77 
predict the cardio-metabolic profile in European adolescents, considering BMI. 78 
Methods and results: 659 adolescents (295 boys) from a cross-sectional European 79 
study were included. Adolescents were classified by metabolic health based on age- and 80 
sex-specific cut-off points for glucose, blood pressure, triglycerides, high density 81 
cholesterol and BMI. C-reactive protein (CRP), tumor necrosis factor alpha (TNF-α), 82 
interleukin (IL-6), complement factors (C3, C4) and cell adhesion molecules were 83 
assessed.  84 
Results: Metabolically abnormal (MA) adolescents had higher values of C3 (p<0.001) 85 
and C4 (p=0.032) compared to those metabolically healthy (MH). C3 concentrations 86 
significantly increased with the deterioration of the metabolic health and BMI 87 
(p<0.001). Adolescents with higher values of CRP had higher probability of being in 88 
the overweight/obese-MH group than those allocated in other categories. Finally, high 89 
C3 and C4 concentrations increased the probability of having an unfavorable 90 
metabolic/BMI status. 91 
Conclusions: Metabolic/BMI status and inflammatory biomarkers are associated, being 92 
the CRP, C3 and C4 the most related inflammatory markers with this condition. C3 and 93 
C4 were associated with the cardio-metabolic health consistently.   94 
Keywords:  Inflammation, metabolic health, metabolic syndrome, inflammatory 95 





Obesity is characterized by an increase of the adipose tissue and this condition is often 100 
related with cardio-metabolic risk factors and inflammation 1. Body mass index (BMI), 101 
the most used anthropometric index to assess obesity, is a strong predictor of CVD 102 
mortality 2,3. However, literature suggests that some subjects with obesity could present 103 
a normal or healthy metabolic profile: the metabolically healthy obesity (MHO), in 104 
contrast to the so-called metabolically abnormal obesity (MAO) 4,5. Currently, there is a 105 
lack of consensus on the definition of the MHO; usually, it is based on the definition for 106 
the metabolic syndrome (MS). In adults, the prevalence of MHO ranges from 10 to 40% 107 
6. In youth, there is a lack of information on prevalence due to the different definitions 108 
used. Ortega et al. 5 recently proposed a definition for youth and adults, aiming to 109 
harmonize the MHO definition, the latter based on the one proposed by Jolliffe and 110 
Janssen 7. 111 
A review on the characterization of the MHO individuals concludes that low 112 
concentrations of inflammatory markers, low visceral adipose tissue deposition and 113 
preserved insulin sensitivity contribute to the MHO phenotype 8. Furthermore, the 114 
potential addition of some of these markers to the definition of the MHO has also been 115 
proposed 9. Evidence suggest that inflammation has a key role in the origin and 116 
development of metabolic disorders 1 and atherosclerosis 10. New biomarkers have been 117 
related with inflammation. For instance, complement factors C3 and C4, depends on 118 
pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) or interleukin 119 
6 (IL-6) 11. Also, cell adhesion molecules have been suggested as markers for 120 
atherosclerosis and their concentrations are elevated during inflammatory processes 12.  121 
 5 
A previous study showed that MHO subjects with low CRP levels had a trend towards 122 
lower coronary heart disease risk than those MHO with high CRP levels and a similar 123 
risk to that of healthy non-obese subjects 13. This study suggests that CRP could help to 124 
identify those MHO individuals who are at low coronary heart disease risk. However, 125 
one study showed similarly adverse cardio metabolic profile in MHO and MAO adults 126 
14.  127 
Adolescents usually have lower prevalence of obesity in comparison with adults. 128 
Specifically, the HELENA sample presented a 3.8 % of obesity in boys and 7.3% in 129 
girls 15. Therefore, the study of the metabolically health status, or the metabolic health 130 
(MH) in overweight/obese adolescents, instead of the MHO seems to be a more feasible 131 
approach in this population, as it has been previously done in the same study16.  132 
To our knowledge there are no studies measuring inflammation in metabolically healthy 133 
and/or metabolically abnormal overweight/obese adolescents. The aims of this study 134 
are: to assess the inflammatory status by metabolic health/body mass index (BMI) 135 
category and, on the other hand, to assess how the increases of the inflammatory 136 
concentrations can predict the cardio-metabolic health profile in European adolescents, 137 





Study design 142 
A cross-sectional multi-center study (n=3528), the HELENA (Healthy Lifestyle in 143 
Europe by Nutrition in Adolescence) study, was conducted between 2006 and 2007 in 144 
10 European cities: Athens and Heraklion, Dortmund, Ghent, Lille, Pecs, Rome, 145 
Stockholm, Vienna and Zaragoza. Design and general procedures of the study have 146 
been previously described17.  147 
 148 
This study was performed according to the ethical guidelines of the Edinburgh revision 149 
of Declaration of Helsinki (2000). In addition, the local Ethics Committees of each 150 
center approved the protocol. Written informed consents were obtained from the 151 
adolescents and their caregivers.   152 
 153 
Study sample 154 
Out of the total HELENA sample, blood collection was randomly performed in 155 
approximately a third of the total sample (n=1089, 31%). 659 participants (295 boys 156 
and 364 girls) met the inclusion criteria of having measured the metabolic biomarkers 157 
for the definition of the healthy/abnormal metabolic status and the inflammatory 158 
biomarkers. 159 
 160 
Physical measurements 161 
Weight was measured with an electronic scale (SECA 861, Seca Ltd) and height were 162 
measured with a stadiometer (SECA 225, Seca Ltd) 18. In addition, body mass index 163 
(BMI) was calculated. Systolic and diastolic blood pressure was measured with an 164 
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automatic oscillometric device (Omron M6). The lowest value of the two 165 
measurements, taken with a difference of 5 minutes, was recorded.  166 
 167 
Physical activity 168 
Levels of physical activity were self-reported using the International Physical Activity 169 
Questionnaire for Adolescents (IPAQ-A) 19. School-related physical activity (including 170 
physical education classes and breaks), transportation, housework, and activities during 171 
leisure time were included in this questionnaire.  172 
 173 
Blood analysis 174 
Detailed description of blood sampling procedures has been published 20. Blood 175 
withdrawal was performed after 10 hours overnight fast. Serum triglycerides, glucose 176 
and high density lipoprotein were measured enzymatically in fresh seru, on the 177 
Dimension RxL clinical chemistry syste (Dade Behring, Schwalbach, Germany) using 178 
the manufacturer’s reagents and instructions. The assessment methods for the CRP, C3 179 
and C4 have been previously described elsewhere 21. Serum cytokines IL-6 and TNF-α 180 
were determined using the High Sensitivity Human Cytokine MILLIPLEX™ MAP kit 181 
(Millipore Corp., Billerica, MA, USA) and collected by flow cytometry (Luminex-100 182 
v.2.3, Luminex Corporation, Austin, TX, USA). The intra- and inter-assay precision 183 
coefficients of variability (CVs) were: 3.5% and 4.5%, respectively, for IL-6; and 3.5% 184 
and 3.8%, respectively, for TNF-α. Detection limits (sensitivity) for all the analyses 185 
were 0.007 mg/l for CRP, 0.01 g/l for C3, 0.002 g/l for C4, 0.1 pg/ml for IL-6, and 0.05 186 
pg/ml for TNF-α. Undetectable values were recorded as the specific detection limit. 187 
Children with values of 0.12 pg/mL for TNF-α and IL-6 were excluded as it was an 188 
assigned value for children with concentration values under the detection curve. The 189 
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serum adhesion molecule sL-selectin was analysed through commercial ELISA kit 190 
(Diaclone, France), the sensitivities of this kit was less than 1 ng/mL for L-selectin, 191 
analyzed by Universal Microplate Spectophotometer (Power WaveTM XS, Biotek® 192 
Instruments, INC USA). 193 
The multiplex assay kit was used to detect for the simultaneous quantification of the 194 
following molecules sE-Selectin, sVCAM-1, sICAM-1, in serum. The samples were 195 
analysed by cytometry (Luminex ®100). The sensitivities of these assays were: Min DC 196 
0.079 ng/mL for sE-Selectin, 0.016 ng/mL for sVCAM-1 and 0.009 ng/mL for sICAM-197 
1. The intra-assay CVs were 11.2% for sE-Selectin, 4.5% for sVCAM-1 and 7.9% for 198 
sICAM-1. 199 
 200 
Definition of MHO and MAO 201 
Ortega et al. 5, recently suggested an harmonization for the definition of MHO in youth, 202 
based on the one by Jolliffe and Janssen for metabolic syndrome 7. In this study, age- 203 
and gender- specific cut-off points for each marker of metabolic syndrome were 204 
developed except for the glucose criteria, considered a marker when the value was 205 
higher than 5.6 mmol/l or 100mg/dl. MHO is defined as 1) being obese/overweight 206 
according to the BMI cut-off points for youth by Cole et al. 22 and 2) no criterion of the 207 
following for the metabolic syndrome: high serum triglycerides (≥150mg/dL), fasting 208 
glucose(≥100mg/dL), systolic or diastolic blood pressure (Systolic ≥ 130 and diastolic 209 
≥85 mm Hg) and low high density lipoprotein cholesterol (<40mg/dL in men and 210 
<50mg/dL in women). MAO was defined when 1 or more of the previous criteria were 211 
met. Waist circumference was excluded as criterion since high waist circumference is 212 
expected in overweight/obese individuals.  213 
 9 
In contrast, metabolically healthy (MH) are those who accomplish having no criterion 214 
of the metabolic syndrome while metabolically abnormal (MA) are those with 1 or 215 
more than 1 criterion, both independently of their BMI status. 216 
 217 
Statistical analysis 218 
Normality of distributions was assessed with the Kolmogorov–Smirnov test. CRP, IL-6, 219 
TNF-α, L-selectin, sE-selectin and sICAM were normalized by natural logarithm 220 
transformation. T-tests were used for comparisons of continuous variables and chi-221 
square test was performed to test the differences between categories.  222 
Two-way analysis of covariance (ANCOVA) with Bonferroni post-hoc correction was 223 
applied to compare mean differences of each biomarker between these categories of 224 
metabolic health/BMI status by sex. The confounders included in this analysis were age 225 
and the self-reported moderate-to-vigorous physical activity. 226 
Finally, four categories combining BMI status and metabolic health were created: 227 
normal weight MH, normal weight MA, overweight/obese-MH and overweight/obese-228 
MA, and then multinomial logistic regression was performed to assess the association 229 
between these categories of metabolic health (dependent) and each marker of 230 
inflammation (independent) adjusting by age, sex and moderate-to-vigorous physical 231 
activity. Results for the C3 and C4 were expressed in change for 0.1 g/L. 232 
Data were managed and analyzed with the IBM SPSS Statistics v.21 (IBM Corp., New 233 





Descriptive characteristics are presented in Table 1. Boys were more frequently 238 
allocated in the MA group (50.7%) than girls (49.3%). Also, those adolescents in the 239 
MA group had higher mean value of BMI (p<0.001). Differences between percentages 240 
of adolescents by BMI status were also found. Adolescents with a MA profile had 241 
higher values of all the metabolic markers included in the definition for metabolic 242 
health: blood pressure (systolic and diastolic), glucose, triglycerides and lower 243 
concentrations of high density lipoprotein cholesterol in comparison with those in the 244 
MH group (all p<0.001). Regarding the inflammatory biomarkers measured, MA 245 
adolescents presented higher concentrations of CRP (p=0.002), C3 (p<0.001) and C4 246 
(p=0.032) than those classified as MH.  247 
In the ANCOVA (Table 2), mean biomarkers concentrations were different according 248 
to the categories of BMI status/metabolic health. In boys (Table 2), significant mean 249 
differences were found in CRP (p=00.001), C3 (p<0.001) and C4 (p<0.001). C3 250 
concentrations increased with the deterioration of the metabolic health and the BMI 251 
status, being higher in the last group, i.e: overweight/obese-MA adolescents. 252 
Overweight/obese-MH adolescents had the highest value of CRP and C4 in boys. In 253 
girls, significant mean differences were found for C3 (p<0.001) being the highest mean 254 
concentration value found in the group of overweight/obese-MA adolescents.  255 
The supplementary table 1 shows the results for the multinomial logistic regression. 256 
This table presents the probability of being in a more unfavorable group of 257 
BMI/metabolic health by the increase of the concentration of the inflammatory 258 
biomarkers. The probability of being in the normal weight-MA or overweight/obese-259 
MH increased in a 17% and in a 58%, respectively, and in a 52% for the 260 
overweight/obese MA per each increase of mg/L of the CRP. Per each additional 0.1 261 
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g/L in C3, the probability of being in the normal weight-MA category was 23%, in the 262 
overweight/obese a 51% and in the overweight/obese-MA a 62%. 263 
In relation to C4, per each 0.1 g/L increases, the probability of being in the normal 264 
weight-MA increased in a 23%; and in a 205% and 126% of being overweight/obese-265 
MH and overweight/obese-MA, respectively. Additionally, per each mg/L increase in 266 
sVCAM-1, the probability of being overweight/obese-MH decreased in a 1%.  267 





Findings from this study suggest that differences in inflammatory biomarkers’ 272 
concentrations were found between MH and MA adolescents. Also, the probability of 273 
being in an unfavorable metabolic/BMI status increased with increasing C3 274 
concentrations.  275 
The prevalence of adults with obesity categorized as MHO, based on 10 population-276 
based cohort studies in 7 European countries has been estimated as 12.1% 5,23 . In youth, 277 
information on MHO is scarce, due to the lack of agreed definition in this population 278 
group. In our sample, 0.8% of the adolescents were classified as MHO while 6.8% were 279 
classified as MH/overweight-obese. This low prevalence of MHO could be due to the 280 
low sample size of this study and the different definitions used for MHO. In previous 281 
studies, prevalence of MH overweight/obese and obese adolescents ranged from 6 to 282 
68% 24,25. In our study, 2.7% of the adolescents were allocated in the MAO group. This 283 
highlights the importance of a common definition already in adolescence to identify 284 
those subjects with a favorable metabolic profile.  285 
A previous study on adult population measured cardio-metabolic risk factors and 286 
inflammation in MHO and MAO individuals and found similar adverse inflammatory 287 
profile in both groups 20. However, when we assessed some inflammatory marker 288 
concentrations by groups, combining cardio-metabolic health and BMI status by sex, 289 
differences in mean concentrations were found. In both sexes, MHO had significantly 290 
higher CRP concentrations than their counterparts. This result contrast with previous 291 
literature as MHO seems to present a favorable inflammatory profile 4,13,26. Moreover, 292 
in our sample, adolescents with high values of CRP, C3, C4 and sVCAM-1 had higher 293 
probability of being in the overweight/obese-MH group in comparison with the normal 294 
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weight-MH. Similar gene expression of visceral adipose tissue and liver has been found 295 
in a previous study, from MHO and MAO patients, with no differences in CRP levels 14. 296 
Also, a comparative study stated that the associations between inflammatory markers 297 
and MHO depend on the definition used 27. 298 
However, the most consistent results across all the analysis were found for the C3. 299 
Overweight/obese-MA subjects had the highest concentrations of the C3 complement 300 
factor. In addition, high C3 concentrations increased the probability of being in an 301 
unfavorable metabolic/BMI status. C3 is recognized as a cardiovascular risk factor as it 302 
has been related with an increased likelihood of future cardiovascular heart disease 303 
(CHD) 28. It has also been associated with metabolic disorders, like adiposity, 304 
dyslipidemia, insulin resistance, liver dysfunction and diabetes 29. Results from the 305 
present study suggest that this relationship between C3 and metabolic disorders is found 306 
already in adolescence, especially on those individuals with the worse metabolic/BMI 307 
status. A previous study in adult population found that C3 concentrations were 308 
consistently lower in the MH individuals 26. Therefore, C3 could be an important 309 
marker for the characterization of the metabolic health. Also C4 was associated with the 310 
probability of being in an unfavorable metabolic/BMI status. C4, along with C3, has 311 
been related with metabolic syndrome 30 and this relationship could be due to their 312 
involvement in the development of visceral adiposity in children and adolescence. 313 
This study has strengths as well as some limitations. First, the cross-sectional design 314 
does not allow establishing causality. Also, blood samples only reflect inflammatory 315 
status at one-time point. The low sample size could be also a limitation. In contrast, this 316 
study has some strengths: the use of traditional and non-traditional biomarkers to reflect 317 
the inflammatory status and the use of a definition for MH based on age- and sex-318 
specific cut-off points as the basis to establish health risk in adolescents, which is more 319 
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appropriate from a clinical perspective. Finally, the use of standardized and harmonized 320 
information of adolescents from 9 European countries is another strength. 321 
In conclusion, these results show that there is an association between some 322 
inflammatory biomarkers and metabolic/BMI status. C3 and C4 seem to be emerging 323 
biomarker related to the cardio-metabolic health, already in adolescence. Likewise, the 324 
increase of some inflammatory markers increased the probability of being in an 325 
overweight/obese-MH status. A unique definition for metabolic health is necessary to 326 
corroborate these results. Further longitudinal studies are needed to understand how 327 
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Table 1. Characteristics of the study sample by cardio-metabolic health status. 436 
437 
MH: metabolically healthy (no criterion of the following: high serum triglycerides (≥150mg/dL), fasting 438 
glucose(≥100mg/dL), systolic or diastolic blood pressure (Systolic ≥ 130 and diastolic ≥85 mm Hg) and 439 
low high density lipoprotein cholesterol (<40mg/dL in men and <50mg/dL in women); MA: 440 
metabolically abnormal (1 or more criteria of the following: high serum triglycerides (≥150mg/dL), 441 
fasting glucose(≥100mg/dL), systolic or diastolic blood pressure (Systolic ≥ 130 and diastolic ≥85 mm 442 
Hg) and low high density lipoprotein cholesterol (<40mg/dL in men and <50mg/dL in women); SD:  443 
standard deviation; BMI: Body mass index; MVPA: moderate to vigorous physical activity; HDL-444 
cholesterol: High density lipoprotein; CRP: C-reactive protein; IL-6: interleukin 6; TNF-α: tumor 445 
MH (n=383) MA (n=276) 
Mean±SD Mean±SD p-value
Age (years) 14.59±1.12 14.96±1.20 <0.001 
Sex N(%) N(%) 
Boys 155 (40.5) 140 (50.7) 0.009 
Girls 228 (59.5) 136 (49.3) 
BMI (kg/m2) 20.17±2.85 22.08±3.63 <0.001 
BMI group by Cole et al. N(%) N(%) 
Normal weight 338 (88.3) 194 (70.3) <0.001 
Overweight/Obese 45 (11.7) 82 (29.7) 
MVPA 779.03±570.08 784.95±607.99 0.898 
Blood pressure 
Systolic (mm Hg) 110.84±8.68 124.09±13.83 <0.001 
Diastolic (mm Hg) 61.88±7.28 68.13±8.97 <0.001 
Glucose (mg/dL) 89.20±5.84 92.50±8.18 <0.001 
Triglycerides (mg/dL) 62.15±22.31 82.90±47.76 <0.001 
HDL-cholesterol 
(mg/dL) 
59.09±9.00 51.59±11.22 <0.001 
CRP* (mg/L) 0.66±1.04 0.91±1.28 0.002 
IL6* (pg/mL) 24.40±32.99 19.59±24.68 0.085 
TNF-α * (pg/mL) 6.65±5.25 6.16±4.77 0.141 
C3 (g/L) 1.09±0.15 1.15±0.17 <0.001 
C4 (g/L) 0.19±0.06 0.21±0.06 0.032 
L-Selectin* (ng/mL) 3624.85±1583.08 3505.61±1355.87 0.985 
sE-Selectin* (ng/mL) 37.19±18.89 36.97±20.95 0.335 
sVCAM-1 (ng/mL) 1293.41±388.97 1270.42±413.48 0.472 
sICAM-1* (ng/mL) 155.43±75.20 173.22±185.95 0.197 
20 
necrosis factor alpha; C3 and C4: complement factors; sVCAM-1: soluble vascular cell adhesion protein 446 
1; sICAM-1: soluble Intercellular Adhesion Molecule. *Log-trangsformed. 447 
 21 
Table 2. Mean differences of the inflammatory biomarkers by group of metabolic/BMI status in boys and girls. Age and moderate-to-vigorous 448 
activity were used as confounders. 449 
Normal weight Overweight/Obese 





Mean ±SD Mean ±SD Mean ±SD Mean ±SD 
CRP (mg/L)* 0.58±0.77 0.79±1.16 1.23±1.98a 1.01±1.16 0.001 
IL6 (pg/mL)* 27.62±35.61 22.65±26.91 34.34±58.25 24.53±31.31 0.176 
TNF-α  (pg/mL)* 7.99±7.19 7.03±6.85 7.17±5.22 6.74±.3.44 0.381 
C3 (g/L) 1.06±0.13 1.10±0.16 1.17±0.14a 1.20±0.15a <0.001 
C4 (g/L) 0.18±0.06 0.19±0.05 0.23±0.07a 0.22±0.07a <0.001 
L-Selectin (ng/mL)* 3785.64±1618.29 3607.07±1344.40 3782.98±2120.99 3369.90±1280.04 0.908 
sE-selectin (ng/mL)* 39.39±18.51 38.39±19.12 43.45±23.52 47.45±31.24 0.649 
sVCAM-1(ng/mL) 1432.63±370.18 1370.99±404.49 1227.95±309.48 1408.76±398.84 0.388 
sICAM-1(ng/mL)* 169.70±69.40 174.10±97.17 167.71±75.09 239.21±416.15 0.886 





Mean ±SD Mean ±SD Mean ±SD Mean ±SD 
CRP (mg/L)* 0.63±1.04 0.87±1.29 0.97±1.06 1.16±1.16 0.070 
IL6 (pg/mL)* 21.32±28.24 16.13±21.65 23.89±22.88 15.20±14.89 0.179 
TNF-α  (pg/mL)* 5.78±3.52 5.64±3.00 5.65±2.44 4.66±2.06 0.897 
C3 (g/L) 1.09±0.16 1.16±0.18a 1.17±0.13 a 1.21±0.18 a 0.001 
C4 (g/L) 0.19±0.06 0.21±0.06 0.24±0.08 0.22±0.05 0.089 
L-Selectin (ng/mL)* 3454.23±1448.89 3401.14±1337.38 4039.05±1851.72 3647.63±1514.56 0.802 
sE-selectin (ng/mL)* 34.80±18.88 31.93±16.32 39.66±13.99 34.38±17.57 0.508 
sVCAM-1(ng/mL) 1225.61±392.78 1155.70±387.10 1149.72±310.45 1150.92±292.92 0.168 
sICAM-1(ng/mL)* 144.37±77.22 153.61±104.71 158.95±78.20 147.91±58.67 0.233 
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 450 
MH: metabolically healthy (no criterion of the following: high serum triglycerides (≥150mg/dL), fasting glucose(≥100mg/dL), systolic or diastolic blood pressure (Systolic ≥ 451 
130 and diastolic ≥85 mm Hg) and low high density lipoprotein cholesterol (<40mg/dL in men and <50mg/dL in women); MA: metabolically abnormal (1 or more criteria of 452 
the following: high serum triglycerides (≥150mg/dL), fasting glucose(≥100mg/dL), systolic or diastolic blood pressure (Systolic ≥ 130 and diastolic ≥85 mm Hg) and low 453 
high density lipoprotein cholesterol (<40mg/dL in men and <50mg/dL in women); MA: metabolically abnormal; SD:  standard deviation; CRP: C-reactive protein; IL-6: 454 
interleukin 6; TNF-α: tumor necrosis factor alpha; C3 and C4: complement factors; sVCAM-1: soluble vascular cell adhesion protein 1; sICAM-1: soluble Intercellular 455 





Figure Legends 460 
461 
Figure 1: Significant results of the multinomial logistic regression to assess the 462 
association between inflammatory biomarkers and BMI/metabolic status adjusted by 463 
sex, tanner and moderate-to-vigorous physical activity. (**) C3 and C4 present changes 464 
per 0.1 g/L. *p<0.05. Normal weight-MH was set as reference group. 465 
466 
467 
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